Значение натрийуретических пептидов в диагностике сердечной недостаточности и других заболеваний

1. ESC Guidelines. Executive summary of the guidelines on the diagnosis and treatment of acute heart failure. The Task Force on Acute Heart Failure of the European Society of Cardiology. Eur. Heart. J. 2005; 26: 384-416.

2. Кeaven M., Kannel W. Survival after the onset of congestive heart failure in Framingham heart study subjects. Circulation 1993; 88: 107-115.

3. Беленков Ю.Н. Определение качества жизни у больных с хронической сердечной недостаточностью. Кардиология 1993; 2: 85-88.

4. Mukoyama M., Nakao K., Nosoda K. et al. Brain natriuretic as a novel cardiac hormone in humans: evidence for a dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J. Clin. Invest. 1991; 87: 1402-1412.

5. Батурова Е.А., Суворов Ю.А. Значение предсердного натрийуретического фактора в регуляции деятельности сердечно-сосудистой системы. Кардиология 1991; 1: 91-93.

6. Goto T., Nobuyki O., Hiromichi M. et al. Usefulness of plasma Braintype natriuretic peptide level to differentiate left ventricular diastolic dysfunction from preserved diastolic function in patients with systolic dysfunction. J. Cardiol. 2005; 95: 1383-1385.

7. Neyses L. Nitsch J, Biegel Th. Erhohung des atrialen naatriuretichen Peptids und der Plasmakatecholamine beiarterieller Hypertonie!Hinweise auf eine Wechselwirkung. Z. Kardiol 1988; 7: 407-412.

8. Pettersson A., Hedner J., Hedner T. et al. Increased plasma levels of atrial natriuretic peptide in patients with congestive heart failure. Europ. Heart J. 1986; 7: 693-696.

9. Сидоренко Б.А., Преображенский Д.В. Диагностика и лечение хронической сердечной недостаточности. М.: Изд-во ЗАО "Пресид-Альянс"; 2002: 88-93.

10. Sudoh T., Kangawa K., Minamino N. et al. A new natriuret! ic peptide in porcine brain. Nature 1988; 332: 78-81.

11. Porter J.G., Arfsten A., Palisi T. et al. Cloning of a cDNA encoding porcine brain natriuretic peptide. J. Biol. Chem 1989; 264: 6689-6692.

12. Levin E., Gardner D.G., Samson W.K. Natriuretic peptides. N. Engl. J. Med. 1998; 339: 321-328.

13. Yoshimura M., Yasue H., Okumura K. et al. Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure. Circulation 1993; 87: 464-469.

14. Yasue H., Obata K., Okumura K. et al. Increased secretion of atrial natriuretic polypeptide from the left ventricle in patients with dilated cardiomyopathy. J. Clin. Invest. 1989; 83: 46-51.

15. Hobbs F.D., Davis R.C., Roalfe A.K. et al. Reliability of N!terminal pro!brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community populations. Br. Med. J. 2002; 324: 1498.

16. Wang T.J. Larson M.G., Levy D. et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am. J. Cardiol. 2002; 90: 254-258.

17. Redfield M.M., Rodeheffer R.J., Jacobsen S.J. et al. Plasmabrain natriuretic peptide concentration: impact of age and gender. J. Am. Coll. Cardiol. 2002; 40: 976-982.

18. Stein B.C., Levin R.I. Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease. Am. Heart. J. 1998; 135: 914-923.

19. Wei C.M., Heublein D.M., Perrella M.A. et al. Natriuretic peptide system in human heart failure. Circulation 1993; 88: 1004-1009.

20. Maeda K., Tsutamoto T., Wada A. et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end!diastolic pressure in patients with symptomatic left ventricular dysfunction. Am. Heart. J. 1998; 135: 825-832.

21. Yamamoto K., Burnett J.C. Jr., Jougasaki M. et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertesion 1996; 28: 988-994.

22. Kruger S., Graf J., Kunz D. et al. Brain natriuretic peptide levels predict functional capacity in patients with chronic heart failure. J. Am. Coll. Cardiol. 2002; 40: 718-722.

23. Hasegawa K., Fujiwara H., Doyama K. et al. Ventricular expression of brain natriuretic peptide in hypertrophic cardiomyopathy. Circulation 1993; 88: 372-380.

24. Dao Q., Krishnaswamy P., Kazanegra R. et al. Utility of B!type natriuretic peptide in the diagnosis of congestive heart failure in an urgent!care setting. J. Am. Coll. Cardiol. 2001; 37: 379-385.

25. Davis M., Espiner E., Richards G. et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet 1994; 343: 440-444.

26. Morrison L.K. Harrison A., Krishnaswamy P. et al. Utility of a rapid B!natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnea. J. Am. Coll. Cardiol. 2002; 39: 202-209.

27. Wieczorek S.J., Wu A.H., Christenson R. et al. A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation. Am. Heart. J. 2002; 144: 834-839.

28. Maisel A.S., Koon J., Krishnaswamy P. et al. Utility of B-natriuretic peptide as a rapid, point!of!care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am. Heart. J. 2001; 141: 367-374.

29. Maisel A.S., Krishnaswamy P., Nowak R.M. et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N. Engl. J. Med. 2002; 347: 161-167.

30. Kiely D., Kennedy N., Pirzada O. et al. Elevated levels of natriuretic peptides in patients with pulmonare throm! boembolism. Respir. Med. 2005; 99: 1286-1291.

31. Krauser D., Donald L., Claudia U. et al. Effect of body mass index on natriuretic peptide levels in patients with acute congestive heart failure: a ProBNP investigation of dysphea in the emergency department (PRIDE) substudy. Am. Heart. J. 2005; 149: 44-50.

32. Rana R., Vlahakis N.E., Daniels C.E. et al. B!type natriuretic peptide in the assessment of acute lung injury and cardiogenic pulmonary edema. Crit. Care Med. 2006; 34: 1941-1946.

33. Berman B., Maisel A. B!type natriuretic peptide (BNP) levels in differentiating congestive heart failure from acute respiratory distress syndrome (ARDS). Circulation 2002; 106: S3191.

34. Jason P., Keang L.T., Hoe L.K. B-type natriuretic peptide: Issues for the intensivist and pulmonologist. Crit. Care Med. 2005; 33: 2094-2103.

35. Hill N.S., Klinger J.R., Warburton R.R. et al. Brain natriuretic peptide: possible role in the modulation of hypoxic pulmonary hypertension. Am. J. Physiol. 1994; 266: 308-315.

36. Leuchte H.H., Heurohr C., Baumgartner R.A. et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am. J. Respir. Crit. Care Med. 2004; 170: 360-365.

37. Leuchte H.H., Holzapfel M., Baumgartner R.A. et al. Clinical significance of brain natriuretic peptide in primary pulmonary hypertension. J. Amer. Coll. Cardiol. 2004; 43: 764-770.

38. Leuchte H.H., Baumgartner R.A., Nounou M.E. et al. Brain natriuretic peptide is a prognostic parameter in chronic lung disease. Am. J. Respir. Crit. Care Med. 2006; 173: 744-750.

39. Charpentier J., Luyt Ch., Fulla Y. et al. Brain!type natriuretic peptide: A marker of myocardial dysfunction and prognosis during severe sepsis. Crit. Care Med. 2004; 32: 660-666.

40. Okumura H., Iuchi K., Yoshida T. et al. Brain natriuretic peptide is a predictor of anthracy!cline!induced cardiotoxicity. Acta Haematol 2000; 104: 158-163.

41. Nousiainen T., Vanninen E., Jantunen E. et al. Neuroendocrine changes during the evolution of doxorubicin-induced left ventricular dysfunction in adult lymphoma patients. Clin. Sci. 2001; 101: 601-607.

42. Goto T., Takase H., Toriyama T. et al. Increased circulating levels of natriuretic peptides predict future cardiac event in patients with chronic hemodialysis. Nephron 2002; 92: 610-615.